Celebrity Inventors
Glam girl Heddy Lamar may have used her good looks to good effect on the silver screen, but she put her smarts to better use as an inventor. During World War II, she co-patented a frequency-switching system for torpedo guidance that was considered years ahead of its time.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8415456 | Substituted IL-15 polypeptides The invention provides IL-15 amino acid sequences with amino acid substitutions that reduce or eliminate deamidation of IL-15 and degradation by-products. The invention also provides DNA sequences that encode the substituted amino acid sequences, a pharmaceutical co... | 04/09/2013 |
| 8383774 | Collectin fusion proteins comprising TNF or trail The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nuclei... | 02/26/2013 |
| 8383775 | Cytokine zalpha11 ligand Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of ... | 02/26/2013 |
| 8377882 | Stabilization of interleukin 6 in serum based solutions Disclosed is a composition including IL-6, an isoform or a fragment thereof, a compound of the formula C10-C18-alkyl trimethylammonium halogenide (I), wherein the compound is saturated or unsaturated and/or substituted or unsubstituted, or a sa... | 02/19/2013 |
| 8362207 | Multi-level specific targeting of cancer cells with IL-13 A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization el... | 01/29/2013 |
| 8361966 | Use of interleukin-11 as therapeutic agent for heart disease The present invention demonstrates the myocardial protective effects of interleukin 11 in vivo, and provides preventive, therapeutic, or other types of drugs for heart disease using interleukin 11 as the active ingredient. The present invention, by utilizing the myo... | 01/29/2013 |
| 8361954 | Use of IL-28 and IL-29 to treat cancer and autoimmune disorders Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 ... | 01/29/2013 |
| 8338569 | FGFR extracellular domain acidic region muteins Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotide... | 12/25/2012 |
| 8329869 | Modified interferon beta polypeptides and their uses Modified interferon beta polypeptides and uses thereof are provided. ... | 12/11/2012 |
| 8283449 | Interleukin-2/soluble TGA-beta type II receptor B conjugates and methods and uses thereof A conjugate protein comprising an IL-2 and a soluble TGF-beta type II receptor type B and its use in cancer immunotherapy are described. ... | 10/09/2012 |
| 8283307 | Treatment of fibrotic disease The invention relates to the use of INSP035 for treatment and/or prevention of fibrotic diseases, in particular of scleroderma. ... | 10/09/2012 |
| 8278418 | Modified animal erythropoietin polypeptides and their uses Modified animal erythropoietin polypeptides and uses thereof are provide. ... | 10/02/2012 |
| 8268967 | Glycopegylated interferon α The present invention provides IFN-α conjugates including IFN-α peptides and modifying groups such as PEG moieties. The IFN-α peptide and modifying group are linked via an intact glycosyl linking group interposed between and covalently attached to the IFN-α pept... | 09/18/2012 |
| 8258263 | Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an a... | 09/04/2012 |
| 8232371 | Modified human interferon polypeptides and their uses Modified interferon polypeptides with at least one non-naturally-encoded amino acid and uses thereof are provided. ... | 07/31/2012 |
| 8193316 | TACI-Fc fusion proteins, methods of making and uses thereof The subject invention relates generally to novel biologically active TACI-Fc fusion proteins that bind to BLyS and/or APRIL and uses thereof. The invention also relates to methods for recombinant production of homogeneous TACI-Fc fusion proteins on a large scale. | 06/05/2012 |
| 8168751 | Interferon alpha mutant and its polyethylene glycol derivative IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety... | 05/01/2012 |
| 8168752 | T cell proteins and nucleotides encoding the same The present invention relates to mouse and human J12 polynucleotides, polypeptide and anti J12 antibody molecules. The J12 is a cytokine that is preferentially expressed in Th2 cells. The polypeptides and/or antibodies described herein can be used in methods for det... | 05/01/2012 |
| 8163879 | Fusion molecules and IL-15 variants The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses ... | 04/24/2012 |
| 8138312 | Compositions for regulation of tumor necrosis factor-alpha The present invention relates to compositions and methods relating to an interleukin18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides compositions and methods for ... | 03/20/2012 |
| 8133976 | Methods of use of the TACI/TACI-L interaction The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the ... | 03/13/2012 |
| 8119771 | Products for altering IL-33 activity and methods thereof Products for altering IL-33 activity including antibodies that specifically bind to an epitope with the polypeptide sequence of IL-33 such as antibodies that specifically bind to a protease cleavage region of IL-33 comprising the amino acid sequence of SEQ ID No. 17... | 02/21/2012 |
| 8106160 | N-terminal modified interferon-alpha A method of reducing formation of non-natural disulfide bonds in a mature IFN-α by adding one or more amino acid residues to its N-terminus cystein. Also disclosed herein is the IFN-α thus modified. ... | 01/31/2012 |
| 8101716 | Human interferon-beta mutein The present invention relates to a human interferon-beta mutein. In particular, the present invention relates to the human interferon-beta mutein having one or two additional sugar chains compared to natural human interferon-beta. ... | 01/24/2012 |
| 8097702 | Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses Modified interferon polypeptides with at least one non-naturally-encoded amino acid and uses thereof are provided. ... | 01/17/2012 |
| 8093356 | Pegylated human interferon polypeptides Modified human interferon polypeptides and uses thereof are provided, including PEGylated human interferon polypeptides with one or more non-naturally encoded amino acids. ... | 01/10/2012 |
| 8067375 | Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor Methods of treating a demyelinating disorder using inhibitors of the lymphotoxin pathway. ... | 11/29/2011 |
| 8058398 | Modified G-CSF polypeptide The present invention relates to granulocyte colony-stimulating factor (“G-CSF”) hybrid molecules which retain the internal core helices of G-CSF. Also provided are pharmaceutical compositions containing hybrid molecules. ... | 11/15/2011 |
| 8048848 | Long-acting interferons and derivatives thereof and methods thereof A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of... | 11/01/2011 |
| 8048988 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can includ... | 11/01/2011 |
| 8048849 | Long-acting polypeptides and methods of producing same A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of ... | 11/01/2011 |
| 8030452 | IFBM'S to promote the specific attachment of target analytes to the surface of orthopedic implants The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related materi... | 10/04/2011 |
| 8022184 | IFBM's to promote the specific attachment of target analytes to the surface of orthopedic implants The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related materi... | 09/20/2011 |
| 8022185 | IFBM's to promote the specific attachment of target analytes to the surface of orthopedic implants The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related materi... | 09/20/2011 |
| 8022183 | IFBM'S to promote the specific attachment of target analytes to the surface of orthopedic implants The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related materi... | 09/20/2011 |
| 8017733 | Polyalkylene polymer compounds and uses thereof The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepa... | 09/13/2011 |
| 7982007 | Cynomolgus toll-like receptor 3 Isolated polynucleotides encoding Cynomolgus monkey Toll-Like Receptor 3 (cynoTLR3), polypeptides obtainable from expression of these polynucleotides, recombinant cells, methods and uses of these are disclosed. ... | 07/19/2011 |
| 7973133 | Inhibitor of endogenous human interferon-gamma The invention relates to an inhibitor of endogenous human interferon-gamma (hIFN-ϝ) in autoimmune diseases, especially in multiple sclerosis. More precisely, the invention relates to inactivated protein derivatives of the hIFN-ϝ with preserved affinity... | 07/05/2011 |
| 7956161 | Interferons of rhesus and cynomolgus origin and uses thereof Disclosed are interferons of Rhesus and Cynomolgus origin and methods of production and use thereof. ... | 06/07/2011 |
| 7951916 | Il-1 related polypeptides The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric p... | 05/31/2011 |
